Pharmaceuticals News and Research

RSS

Pharmaceutical research centre led by the University of Limerick to receive investment from Science Foundation Ireland

A research centre led by the University of Limerick dedicated to supporting the pharmaceutical industry in Ireland will benefit from today’s announcement of €300 million investment by Science Foundation Ireland. The Irish pharmaceutical industry supports over 60,000 Irish jobs and exports over €50 billion annually.

26 Feb 2013

4SC Discovery enters exclusive research and license agreement with LEO Pharma

LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.

26 Feb 2013

Finding solutions to global health problems might mean creating more risk

"Scientists are aware that their interventions in the natural world will have unintended effects, and in order to behave ethically, these potential risks must be considered," Maggie Koerth-Baker, science editor at BoingBoing.net, writes in a New York Times opinion piece, adding, "Even something as innocuous as a mosquito net may carry a considerable downside."

26 Feb 2013

Sius single-use tangential flow filtration skid from Novasep

Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the launch of its Sius single-use tangential flow filtration (TFF) skid.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

Glide Pharma announces completion of $21.4 million investment round

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.

26 Feb 2013

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Opioids are main contributor to fatal overdoses

The number of deaths from drug overdoses in the United States in 2010 rose for the 11th consecutive year, show data from the National Center for Health Statistics.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Comprehensive portfolio of antiretroviral products from Mylan

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products.

25 Feb 2013

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.

25 Feb 2013

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill.

25 Feb 2013

FDA approves Amneal’s generic Suboxone to treat opioid drug dependence

Amneal Pharmaceuticals, LLC, the 7th largest generic drug manufacturer in the U.S. market, has received U.S. FDA approval for one of the first generic versions of Suboxone sublingual tablets for maintenance treatment of opioid drug dependence.

25 Feb 2013

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA).

23 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

IntegraGen, Lab21 collaborate to develop new microRNA assay for colorectal cancer

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

22 Feb 2013

Research on animal models demonstrates that antidepressants are not a cure as such

We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.

22 Feb 2013

Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics

Breast cancer is a major concern throughout the world. It is the number 1 cancer among women and in the Western world it generates approximately one new case per minute: 24 hours a day 7 days a week.

22 Feb 2013